文献速递肿瘤 PET/CT放射性药物与辐射防护

ABT-806i(111In标记抗EGFR抗体)的I期与生物分布研究

A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
PubMed 文献 · J Nucl Med · 2021-01-28

本研究评估了肿瘤特异性抗EGFR抗体ABT-806的111In标记物ABT-806i的安全性、生物分布与药代动力学,并观察重复给予ABT-806对受体占位的影响。结果显示ABT-806i无输注相关毒性,正常组织摄取低,血液半衰期为6.0±1.5天,肿瘤摄取与存档组织EGFR表达不相关,间隔ABT-806治疗未改变ABT-806i摄取。

要点

  • ABT-806i无输注相关毒性,正常组织摄取低,辐射剂量可接受。
  • ABT-806i肿瘤摄取与存档肿瘤EGFR表达不相关。
  • 间隔ABT-806治疗未改变ABT-806i摄取,提示肿瘤EGFR表达稳定。

核心结论

  • ABT-806i可实现肿瘤EGFR构象表达的实时成像,辐射剂量学可接受,较存档组织能提供额外的抗原表达信息。

研究设计与样本

  • I期研究,队列1纳入6例晚期肿瘤患者接受ABT-806i单次给药并行SPECT及全身平面扫描。
  • 队列2纳入12例患者,初始成像同队列1,随后接受3剂未标记ABT-806后再行ABT-806i成像。

主要发现

  • 未观察到ABT-806i输注相关毒性。
  • ABT-806i在正常组织摄取极低,血液清除半衰期为6.0±1.5天。
  • ABT-806i对男性的平均有效剂量为0.137 mSv/MBq,对女性为0.183 mSv/MBq。
  • ABT-806i肿瘤摄取存在差异,且与存档肿瘤EGFR表达不相关。
  • 间隔ABT-806治疗后ABT-806i摄取无变化,提示肿瘤EGFR表达稳定。

关键数值与推荐

  • 入组患者为可能表达EGFR/EGFRvIII的晚期肿瘤,体能状态与器官功能充分,且具有RECIST 1.1可测量病灶。

临床怎么用

  • ABT-806i可用于实时成像肿瘤EGFR构象表达,辅助基于EGFR的治疗患者选择及耐药研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of 111In-radiolabeled ABT-806 (ABT-806i) and effects of repeated doses of ABT-806 on receptor occupancy. Methods: Eligible patients had advanced tumors likely to express EGFR/EGFRvIII; adequate performance status and organ function; and measurable disease by RECIST 1.1. In cohort 1, 6 patients received a bolus administration of ABT-806i and underwent SPECT followed by whole-body planar scans. In cohort 2, 12 patients were imaged similarly as in 1 initially; thereafter, they received 3 doses of unlabeled ABT-806, before another dose of ABT-806i with associated SPECT and whole-body planar scans. At the end of both cohorts, patients who had stable or responding disease were able to enroll into an extension study (M12-326) in which they received unlabeled ABT-806 every 2 wk until disease progression, withdrawal of consent, or intolerable toxicity. Results: No toxicity related to ABT-806i infusion was observed. ABT-806i showed minimal uptake in normal tissues and cleared gradually from blood with a half-life of 6.0 ± 1.5 d. The mean effective dose of ABT-806i was 0.137 mSv/MBq for males and 0.183 mSv/MBq for females. ABT-806i tumor uptake varied and did not correlate with archived tumor EGFR expression. No change in ABT-806i uptake was observed after interval ABT-806 treatment, indicating stable EGFR expression in tumor. The patient with highest tumor uptake of ABT-806i had advanced head and neck cancer and experienced a partial response. Conclusion: ABT-806i allows for real-time imaging of EGFR conformational expression in tumors, has an acceptable radiation dosimetry, and provides important additional information about antigen expression compared with standard approaches using archival tissue. Its role to assist in patient selection for EGFR-based therapeutics and investigate treatment resistance should be further investigated.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gan HK, Burge M, Solomon B, et al. A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. J Nucl Med. 2021. PMID: 33509972. doi:10.2967/jnumed.120.253146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。